Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide

Toulmonde,Maud; Démolis,Pascal; Houédé,Nadine

doi:10.3892/etm.2010.138

Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide

Authors:
- Maud Toulmonde
- Pascal Démolis
- Nadine Houédé
View Affiliations

Affiliations: Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, 33076 Bordeaux Cedex, France
Published online on: August 26, 2010 https://doi.org/10.3892/etm.2010.138
Pages: 1005-1011

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate carcinoma is the most common cancer in men. Hormone-resistance is the natural history of this metastatic disease and requires the use of docetaxel as the standard chemotherapy. At present, there is no approved second-line treatment. Here, we report a combination of treatment with Adriamycin and ifosfamide in a series of 7 relatively young patients with an average age of 57 years at the time of diagnosis. Chemotherapy was administered over 3 days with the following schedule: 20 mg/m2 Adriamycin per day and 1-1.5 mg/m2 ifosfamide per day, in association with Uromitexan. Treatment was repeated every 3 weeks. Three biological responses, one CT scan response, one bone scan response and two CT scan stabilizations, were obtained. Mean survival following this combination was 6.6 months, and over 26 months after first-line chemotherapy. Tolerance was good with the use of granulocyte-colony stimulating factors. Our observations clearly show that the use of this type of salvage therapy for relatively young patients in good physical condition should be further assessed in a clinical trial, particularly when different lines of chemotherapy are required.

View Figures

View References

1.	Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ and Auvinen A; ERSPC Investigators: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 13:1320–1328. 2009.PubMed/NCBI
2.	Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK and Berg CD; PLCO Project Team: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 13:1310–1319. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Vollmer RT, Kantoff PW, Dawson NA and Vogelzang NJ: A prognostic score for hormone-refractory prostate cancer: analysis of two Cancer and Leukemia Group B studies. Clin Cancer Res. 5:831–837. 1999.PubMed/NCBI
4.	Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA and Vogelzang NJ: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 21:1232–1237. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Yagoda A and Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 71:1098–1109. 1993. View Article : Google Scholar : PubMed/NCBI
6.	Ferro MA, Gillatt D, Symes MO and Smith PJ: High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology. 34:134–138. 1989. View Article : Google Scholar : PubMed/NCBI
7.	Smith DC, Dunn RL, Strawderman MS and Pienta KJ: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 16:1835–1843. 1998.PubMed/NCBI
8.	Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M and Fossa SD: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 11:607–615. 1993.PubMed/NCBI
9.	Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, Ding C, Wang W, Horak ID and Kremer AB: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 91:244–251. 1999. View Article : Google Scholar
10.	Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 98:516–521. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 17:3461–3467. 1999.
12.	Scher HI, Halabi S, Tannock I, et al: Prostate Cancer Clinical Trials Working Group: design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 26:1148–1159. 2008. View Article : Google Scholar
13.	Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
15.	Winquist E, Waldron T, Berry S, Ernst DS, Hotte S and Lukka H: Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care’s Genitourinary Cancer Disease Site Group. BMC Cancer. 6:1122006.PubMed/NCBI
16.	Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M and Roth B: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 17:3160–3166. 1999.
17.	Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, Larsen E, Mogensen P, Mommsen S and Rosenkilde P: Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol. 157:929–934. 1997. View Article : Google Scholar
18.	Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP, Beuzeboc P, Demkow T and Oudard S: Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol. 15:1613–1621. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP and Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 17:2506–2513. 1999.PubMed/NCBI
20.	Berry W, Dakhil S, Modiano M, Gregurich M and Asmar L: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 168:2439–2443. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM and Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 14:1756–1764. 1996.
22.	Petrioli R, Fiaschi AI, Francini E, Pascucci A and Francini G: The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev. 34:710–718. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Torti FM, Aston D, Lum BL, Kohler M, Williams R, Spaulding JT, Shortliffe L and Freiha FS: Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol. 1:477–482. 1983.PubMed/NCBI
24.	Delaere KP, Leliefeld H, Peulen F, Stapper EW, Smeets J and Wils J: Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma. Br J Urol. 70:641–642. 1992. View Article : Google Scholar : PubMed/NCBI
25.	Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A and Mondillo S: Weekly chemotherapy in advanced prostatic cancer. Br J Cancer. 67:1430–1436. 1993. View Article : Google Scholar : PubMed/NCBI
26.	Petrioli R, Fiaschi AI, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Manganelli A, Salvestrini F and Francini G: Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer. 87:720–725. 2002. View Article : Google Scholar : PubMed/NCBI
27.	Neri B, Barbagli G, Bellesi P, Di Loro R, Lombardi V, Lombardo C, Magrini T, Mottola A, Nicita G, Palminteri E, Ponchietti R, Raugei A and Intini C: Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer. Anticancer Res. 17:3817–3820. 1997.PubMed/NCBI
28.	Van Andel G, Fernandez de Moral P, Caris CT, Carpentier P, Wils J, de Bruin MJ, Witjes JA, Debruyne FM and Witjes WP: A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. World J Urol. 21:177–182. 2003.
29.	Laurie JA, Hahn RG, Therneau TM, Patel SR, Mailliard JA, Windschitl HE, Twito DI, Morton RF and Krook JE: Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer. 69:1440–1444. 1992. View Article : Google Scholar
30.	Stephens RL, Vaughn C, Lane M, Costanzi J, O’Bryan R, Balcerzak SP, Levin H, Frank J and Coltman CA Jr: Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer/ A randomized Southwest Oncology Group study. Cancer. 53:406–410. 1984. View Article : Google Scholar : PubMed/NCBI
31.	Saxman S, Ansari R, Drasga R, Miller M, Wheeler B, McClean J and Einhorn L: Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group Study. Cancer. 70:2488–2492. 1992. View Article : Google Scholar
32.	Bramwell VH, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol. 31(Suppl 2): 180–184. 1993.PubMed/NCBI
33.	Blum RH, Edmonson J, Ryan L and Pelletier L: Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 31(Suppl 2): 238–240. 1993.PubMed/NCBI
34.	Hervonen Lehtinen T, Tammela TL and Kellokumpu-Lehtinen P: A randomised dose finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC). J Exp Clin Cancer Res. 21:177–180. 2002.PubMed/NCBI
35.	Williamson SK, Wolf MK, Eisenberger MA, O’Rourke MA, Brannon W and Crawford ED: Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Am J Clin Oncol. 19:368–370. 1996. View Article : Google Scholar : PubMed/NCBI
36.	Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F and Francini G: Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology. 69:142–146. 2007. View Article : Google Scholar : PubMed/NCBI